46 research outputs found
Hydrodynamical Description of 200 A GeV/c S+Au Collisions: Hadron and Electromagnetic Spectra
We study relativistic S+Au collisions at 200 A GeV/c using a hydrodynamical
approach. We test various equations of state (EOSs), which are used to describe
the strongly interacting matter at densities attainable in the CERN-SPS heavy
ion experiments. For each EOS, suitable initial conditions can be determined to
reproduce the experimental hadron spectra; this emphasizes the ambiguity
between the initial conditions and the EOS in such an approach. Simultaneously,
we calculate the resulting thermal photon and dielectron spectra, and compare
with experiments. If one allows the excitation of resonance states with
increasing temperature, the electro-magnetic signals from scenarios with and
without phase transition are very similar and are not resolvable within the
current experimental resolution. With regard to the CERES dilepton data, none
of the EOSs considered, in conjunction with the standard leading order dilepton
rates, succeed in reproducing the observed excess of dileptons below the rho
peak. Our work, however, suggests that an improved measurement of the photon
and dilepton spectra has the potential to strongly constrain the EOS.Comment: Uses REVTeX, 48 pages, 13 Postscript figure
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers
INTRODUCTION: Basal-phenotype or basal-like breast cancers are characterized by basal epithelium cytokeratin (CK5/14/17) expression, negative estrogen receptor (ER) status and distinct gene expression signature. We studied the clinical and biological features of the basal-phenotype tumors determined by immunohistochemistry (IHC) and cDNA microarrays especially within the ER-negative subgroup. METHODS: IHC was used to evaluate the CK5/14 status of 445 stage II breast cancers. The gene expression signature of the CK5/14 immunopositive tumors was investigated within a subset (100) of the breast tumors (including 50 ER-negative tumors) with a cDNA microarray. Survival for basal-phenotype tumors as determined by CK5/14 IHC and gene expression signature was assessed. RESULTS: From the 375 analyzable tumor specimens, 48 (13%) were immunohistochemically positive for CK5/14. We found adverse distant disease-free survival for the CK5/14-positive tumors during the first years (3 years hazard ratio (HR) 2.23, 95% confidence interval (CI) 1.17 to 4.24, p = 0.01; 5 years HR 1.80, 95% CI 1.02 to 3.15, p = 0.04) but the significance was lost at the end of the follow-up period (10 years HR 1.43, 95% CI 0.84 to 2.43, p = 0.19). Gene expression profiles of immunohistochemically determined CK5/14-positive tumors within the ER-negative tumor group implicated 1,713 differently expressed genes (p < 0.05). Hierarchical clustering analysis with the top 500 of these genes formed one basal-like and a non-basal-like cluster also within the ER-negative tumor entity. A highly concordant classification could be constructed with a published gene set (Sorlie's intrinsic gene set, concordance 90%). Both gene sets identified a basal-like cluster that included most of the CK5/14-positive tumors, but also immunohistochemically CK5/14-negative tumors. Within the ER-negative tumor entity there was no survival difference between the non-basal and basal-like tumors as identified by immunohistochemical or gene-expression-based classification. CONCLUSION: Basal cytokeratin-positive tumors have a biologically distinct gene expression signature from other ER-negative tumors. Even if basal cytokeratin expression predicts early relapse among non-selected tumors, the clinical outcome of basal tumors is similar to non-basal ER-negative tumors. Immunohistochemically basal cytokeratin-positive tumors almost always belong to the basal-like gene expression profile, but this cluster also includes few basal cytokeratin-negative tumors